Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/41680
Title: Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Authors: 
Mesh: 
Issue Date: 2017
Citation: Oncologist.2017 04;(22)4:375-e30
Abstract: These negative phase II results for parsatuzumab highlight the challenges of developing an agent intended to enhance the efficacy of vascular endothelial growth factor inhibition without the benefit of validated pharmacodynamic biomarkers or strong predictive biomarker hypotheses.Any further clinical development of anti-EGFL7 is likely to require new mechanistic insights and biomarker development for antiangiogenic agents.
PMID: 28275117
URI: https://hdl.handle.net/20.500.12530/41680
Rights: openAccess
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
PMC5388369.pdf1.33 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.